

Rafael Bejar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5078294/publications.pdf>

Version: 2024-02-01

71
papers

9,022
citations

147566

31
h-index

110170

64
g-index

76
all docs

76
docs citations

76
times ranked

8677
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. <i>Blood</i> , 2015, 126, 9-16.	0.6	1,493
2	Clinical Effect of Point Mutations in Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2011, 364, 2496-2506.	13.9	1,444
3	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> , 2022, 36, 1703-1719.	3.3	1,211
4	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. <i>Blood</i> , 2014, 124, 2705-2712.	0.6	486
5	Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2012, 30, 3376-3382.	0.8	419
6	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020, 26, 1549-1556.	15.2	372
7	Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 2691-2698.	0.8	359
8	Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2011, 29, 504-515.	0.8	288
9	MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. <i>Blood</i> , 2015, 126, 2355-2361.	0.6	280
10	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
11	Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 60-87.	2.3	254
12	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. <i>Leukemia</i> , 2019, 33, 1747-1758.	3.3	195
13	<i>SF3B1</i> -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. <i>Blood</i> , 2020, 136, 157-170.	0.6	195
14	Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS. <i>Cancer Cell</i> , 2014, 26, 509-520.	7.7	158
15	Recent developments in myelodysplastic syndromes. <i>Blood</i> , 2014, 124, 2793-2803.	0.6	147
16	Ageing Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia. <i>Cancer Discovery</i> , 2019, 9, 1080-1101.	7.7	119
17	Precancer Atlas to Drive Precision Prevention Trials. <i>Cancer Research</i> , 2017, 77, 1510-1541.	0.4	116
18	Transgenic Calmodulin-Dependent Protein Kinase II Activation: Dose-Dependent Effects on Synaptic Plasticity, Learning, and Memory. <i>Journal of Neuroscience</i> , 2002, 22, 5719-5726.	1.7	92

#	ARTICLE	IF	CITATIONS
19	Clinical and genetic predictors of prognosis in myelodysplastic syndromes. <i>Haematologica</i> , 2014, 99, 956-964.	1.7	91
20	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. <i>Blood</i> , 2015, 126, 907-907.	0.6	85
21	The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine. <i>Journal of Molecular Biology</i> , 2018, 430, 2875-2899.	2.0	72
22	Managing Clonal Hematopoiesis in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 7-11.	0.8	60
23	MDS overlap disorders and diagnostic boundaries. <i>Blood</i> , 2019, 133, 1086-1095.	0.6	58
24	Leveraging premalignant biology for immune-based cancer prevention. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10750-10758.	3.3	57
25	Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. <i>Cancers</i> , 2019, 11, 11.	1.7	46
26	Splicing Factor Mutations in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 907, 215-228.	0.8	45
27	Implications of molecular genetic diversity in myelodysplastic syndromes. <i>Current Opinion in Hematology</i> , 2017, 24, 73-78.	1.2	44
28	X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation. <i>Journal of Clinical Investigation</i> , 2015, 125, 1665-1669.	3.9	43
29	Myelodysplastic Syndromes, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 261-272.	2.3	40
30	Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators. <i>Rna</i> , 2016, 22, 1535-1549.	1.6	40
31	Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling. <i>Haematologica</i> , 2019, 104, e388-e392.	1.7	40
32	Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 282-291.	1.2	35
33	DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes. <i>Blood Advances</i> , 2019, 3, 2845-2858.	2.5	32
34	The Genetic Basis of Myelodysplastic Syndromes. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 295-315.	0.9	28
35	Prognostic models in myelodysplastic syndromes. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 504-510.	0.9	28
36	Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 461-467.	1.2	25

#	ARTICLE	IF	CITATIONS
37	Clonal hematopoiesis in cancer. <i>Experimental Hematology</i> , 2020, 83, 105-112.	0.2	24
38	What biologic factors predict for transformation to AML?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 341-345.	0.7	22
39	The effect of autonomous alpha-CaMKII expression on sensory responses and experience-dependent plasticity in mouse barrel cortex. <i>Neuropharmacology</i> , 2001, 41, 771-778.	2.0	20
40	Clonal Hematopoiesis in Aging. <i>Current Stem Cell Reports</i> , 2018, 4, 209-219.	0.7	18
41	Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation. <i>Blood</i> , 2019, 134, 1730-1744.	0.6	17
42	Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. <i>Leukemia Research</i> , 2017, 52, 1-7.	0.4	14
43	What lies beyond del(5q) in myelodysplastic syndrome?. <i>Haematologica</i> , 2013, 98, 1819-1821.	1.7	13
44	Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. <i>BMC Cancer</i> , 2016, 16, 652.	1.1	12
45	Myelodysplastic Syndromes: Recent Advancements in Risk Stratification and Unmet Therapeutic Challenges. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e256-e270.	1.8	12
46	The importance of subclonal genetic events in MDS. <i>Blood</i> , 2013, 122, 3550-3551.	0.6	11
47	DMSO Increases Mutation Scanning Detection Sensitivity of High-Resolution Melting in Clinical Samples. <i>Clinical Chemistry</i> , 2015, 61, 1354-1362.	1.5	9
48	New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 480-494.	1.8	9
49	SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 613-620.	0.2	8
50	In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden. <i>Cytotherapy</i> , 2021, 23, 320-328.	0.3	8
51	New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 480-494.	1.8	8
52	The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 131-135.	2.3	7
53	Adoptive transfer of neoantigen-specific T-cell therapy is feasible in older patients with higher-risk myelodysplastic syndrome. <i>Cytotherapy</i> , 2021, 23, 236-241.	0.3	7
54	Somatic Mutations Indicative of Clonal Hematopoiesis Are Present in a Large Fraction of Cytopenic Patients Who Lack Diagnostic Evidence of MDS. <i>Blood</i> , 2014, 124, 3272-3272.	0.6	7

#	ARTICLE	IF	CITATIONS
55	TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee. <i>Blood</i> , 2014, 124, 532-532.	0.6	6
56	<i>JAK2</i> double minutes with resultant simultaneous amplification of <i>JAK2</i> and <i>CD274</i> in a therapy-related myelodysplastic syndrome evolving into an acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 566-570.	1.2	5
57	Validation of a Prognostic Model and the Impact of SF3B1, DNMT3A, and Other Mutations in 289 Genetically Characterized Lower Risk MDS Patient Samples. <i>Blood</i> , 2011, 118, 969-969.	0.6	5
58	Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. <i>Leukemia and Lymphoma</i> , 2020, 61, 1455-1464.	0.6	4
59	5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia Cells. <i>Molecular Cancer Research</i> , 2021, 19, 451-464.	1.5	3
60	Indolent T-cell prolymphocytic leukemia with no expression of surface T-cell receptors or surface CD3. <i>International Journal of Laboratory Hematology</i> , 2021, 43, O224-O226.	0.7	3
61	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 311-311.	0.6	3
62	Myelodysplastic Syndromes: Recent Advancements in Risk Stratification and Unmet Therapeutic Challenges. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e256-e270.	1.8	2
63	DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with Hypomethylating Agents. <i>Blood</i> , 2020, 136, 29-30.	0.6	1
64	Myelodysplasia. , 0, , 156-166.		0
65	How do molecular aberrations guide therapy in MDS?. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101324.	0.7	0
66	Point Mutations In Myelodysplastic Syndromes Are Associated with Clinical Features and Are Independent Predictors of Overall Survival. <i>Blood</i> , 2010, 116, 300-300.	0.6	0
67	MYBL2 Is a Candidate Tumor Suppressor Gene In MDS. <i>Blood</i> , 2010, 116, 1865-1865.	0.6	0
68	Board Practice 1. , 2012, , 1062-1074.		0
69	Next generation sequencing to reveal potentially actionable alterations in the majority of patients with hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23133-e23133.	0.8	0
70	Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. <i>Hematological Oncology</i> , 2022, 40, 491-504.	0.8	0
71	Improving Patient Understanding and Outcomes in Myelodysplastic Syndromes - An Animated Patient Guide to MDS with Visual Formats of Learning.. <i>Leukemia Research Reports</i> , 2022, , 100328.	0.2	0